Drug Trial Radar · NCT03677141
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Mar 8, 2019
Primary completion
Oct 12, 2023
Study completion Oct 12, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).
Conditions
- B-cell Non-Hodgkin Lymphoma
Interventions
MosunetuzumabDrug
Participants will receive intravenous (IV) mosunetuzumab.
Polatuzumab VedotinDrug
Participants will receive polatuzumab vedotin via IV.
RituxumabDrug
Participants will receive rituxumab via IV.
CyclophosphamideDrug
Participants will receive cyclophosphamide via IV.
DoxorubicinDrug
Participants will receive doxorubicin via IV.
VincristineDrug
Participants will receive vincristine via IV.
PrednisoneDrug
Participants will receive oral prednisone.
TocilizumabDrug
Participants will receive tocilizumab via IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)Time frame: 6-8 weeks after either C6D1 or last dose of study treatment
Locations
41 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of California; Moores Cancer Center
La Jolla, California
University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica
Santa Monica, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Miami Miller School of Medicine
Miami, Florida
University of Kansas Cancer Center
Westwood, Kansas
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Cancer Center
Rochester, Minnesota
Rhode Island Hospital
Providence, Rhode Island
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Scott and White Hospital; Cancer Center
Temple, Texas
Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin
Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU
Salzburg, Austria
LKH Steyr
Steyr, Austria
Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Hanusch-Krankenhaus
Vienna, Austria
CHU Henri Mondor; Service d'Oncologie Medicale
Créteil, France
Centre Leon Berard
Lyon, France
Hôpital Saint-Louis
Paris, France
Centre Henri Becquerel- Centre de Lutte Contre le Cancer
Saint-Herblain, France
Gustave Roussy
Villejuif, France
Maria Sklodowska-Curie Memorial Cancer Centre
Gliwice, Poland
Ma?opolskie Centrum Medyczne
Krakow, Poland
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka
Słupsk, Poland
Instytut Hematologii i Transfuzjologii; Klinika Zaburze? Hemostazy i Chorób Wewn?trznych
Warsaw, Poland
Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku
Wroc?aw, Poland
Pusan National University Yangsan Hospital
Gyeongsangnam-do, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital San Pedro de Alcantara; Servicio de Hematología
Cáceres, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Institut Catala d?Oncologia Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.